Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
Biomarkers and Dysplastic Respiratory Epithelium
Who can join
As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.
- Age
- 21 Years to 90 Years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
- Compensation
- Not stated
Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.
What to expect
No one can promise a trial will help you personally — that is what the research is trying to find out.
What participation involves
- Procedures mentioned: Biopsies
Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.
Show the study's own words
- "Secondary * Establish a tissue repository of normal and dysplastic respiratory epithelium from endobronchial forceps and brush biopsy tissue from these patients and from normal volunteers."
- Compensation
- Not stated
- Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
- Participants are monitored closely by the research team throughout the study.
- Some participants may receive access to an investigational treatment, which is still being studied.
- Your participation helps researchers learn whether this approach could help future patients.
About this study
RATIONALE: Studying samples of sputum and tissue in the laboratory from patients with dysplasia or cancer may help doctors identify and learn more about biomarkers related to cancer. It may also help the study of cancer in the future. PURPOSE: This laboratory study is looking at biomarkers in patients with respiratory tract dysplasia or lung cancer, head and neck cancer, or aerodigestive tract cancer.
Compensation is read from the study's own description and may be missing — always confirm with the study team.
Eligibility
Official eligibility criteria
Inclusion Criteria: * Diagnosis of extensive and severe dysplasia of the respiratory epithelium * Those without dysplasia of the respiratory epithelium * Recruited from the SPORE Tissue Procurement Screening Project or by private or academic physicians (for patients with moderate or severe dysplasia) * Survived 1 or more aerodigestive system carcinoma for ≥ 1 year * Completely resected stage I non-small cell cancer * Undergoing any of the following procedures: * Routine panendoscopy for patients with head and neck cancer * Resection of a bronchogenic carcinoma * Bronchoscopy for diagnosis or staging of suspected lung cancer * Subsequent bronchoscopy for surveillance or monitoring of response to endobronchial treatment in patients with prior high-grade dysplasia or worse * No asthma * No lung disease * No respiratory illness within the past 2 weeks Patients suspected of or at risk for neoplastic lung disease who are undergoing a bronchoscopy in which differential diagnostic considerations may include multiple other etiologies such as infection and other processes. * Patients without dysplasia will be: patients undergoing clinically indicated bronchoscopy for conditions other than suspected lung cancer. PATIENT CHARACTERISTICS: * No clinically apparent bleeding diathesis * No known bleeding disorder * No anginal * No clinically active coronary artery disease * No multifocal premature ventricular contractions * No poorly controlled congestive heart failure * No myocardial infarction within the past 6 weeks * No cardiac dysrhythmia that is potentially life threatening * Well-controlled atrial fibrillation or rare (\< 2/min) premature ventricular contractions allowed * No ventricular tachycardia or supraventricular tachycardia with a rapid ventricular response * No other serious medical condition that would preclude a patient from undergoing a bronchoscopy * No acute bronchitis or pneumonia within the past 8 weeks except when clinically proven as a possible result of lung cancer * No hypoxemia (i.e., \< 90% saturation with supplemental oxygen) before bronchoscopy PRIOR CONCURRENT THERAPY: * See Disease Characteristics
Study sites (1)
CO
- University of Colorado Cancer Center at UC Health Sciences Center · Aurora, CO 80045Clinical Trials Office - University of Colorado Cancer Center · Study contact · 303-724-1657More trials in Aurora